Fate Therapeutics, Inc. (FATE): Price and Financial Metrics


Fate Therapeutics, Inc. (FATE): $26.25

-0.55 (-2.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FATE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FATE POWR Grades


  • Value is the dimension where FATE ranks best; there it ranks ahead of 52.89% of US stocks.
  • The strongest trend for FATE is in Growth, which has been heading down over the past 179 days.
  • FATE's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

FATE Stock Summary

  • Of note is the ratio of Fate Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.27% of US stocks have a lower such ratio.
  • FATE's price/sales ratio is 72.42; that's higher than the P/S ratio of 97.04% of US stocks.
  • Revenue growth over the past 12 months for Fate Therapeutics Inc comes in at 77.66%, a number that bests 89.18% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FATE, based on their financial statements, market capitalization, and price volatility, are MORF, NKTR, MRTX, AVIR, and CARA.
  • Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.

FATE Valuation Summary

  • In comparison to the median Healthcare stock, FATE's price/sales ratio is 1179.3% higher, now standing at 145.2.
  • Over the past 96 months, FATE's price/earnings ratio has gone down 25.6.
  • Over the past 96 months, FATE's price/sales ratio has gone up 80.

Below are key valuation metrics over time for FATE.

Stock Date P/S P/B P/E EV/EBIT
FATE 2021-08-31 145.2 9.3 -32.9 -33.0
FATE 2021-08-30 142.2 9.1 -32.2 -32.3
FATE 2021-08-27 144.0 9.2 -32.6 -32.7
FATE 2021-08-26 141.3 9.0 -32.0 -32.1
FATE 2021-08-25 144.6 9.2 -32.7 -32.8
FATE 2021-08-24 141.8 9.1 -32.1 -32.2

FATE Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at -267.06%.
  • Its year over year net cashflow from operations growth rate is now at 57.07%.
  • Its 2 year cash and equivalents growth rate is now at 198.46%.
Over the past 70 months, FATE's revenue has gone up $52,093,000.

The table below shows FATE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 55.846 -162.87 -212.151
2021-09-30 54.675 -113.241 -196.641
2021-06-30 48.008 -110.599 -212.017
2021-03-31 40.061 -39.652 -184.956
2020-12-31 31.434 -39.229 -173.387
2020-09-30 18.34 -44.1 -148.578

FATE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FATE has a Quality Grade of D, ranking ahead of 19.68% of graded US stocks.
  • FATE's asset turnover comes in at 0.058 -- ranking 313th of 680 Pharmaceutical Products stocks.
  • RMTI, SYBX, and PTE are the stocks whose asset turnover ratios are most correlated with FATE.

The table below shows FATE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.058 1 -0.324
2021-03-31 0.054 1 -0.384
2020-12-31 0.057 1 -0.550
2020-09-30 0.039 1 -0.586
2020-06-30 0.033 1 -0.572
2020-03-31 0.036 1 -0.625

FATE Price Target

For more insight on analysts targets of FATE, see our FATE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $109.83 Average Broker Recommendation 1.47 (Moderate Buy)

FATE Stock Price Chart Interactive Chart >

Price chart for FATE

FATE Price/Volume Stats

Current price $26.25 52-week high $97.43
Prev. close $26.80 52-week low $17.10
Day low $25.22 Volume 1,655,100
Day high $26.95 Avg. volume 1,493,696
50-day MA $25.65 Dividend yield N/A
200-day MA $43.25 Market Cap 2.54B

Fate Therapeutics, Inc. (FATE) Company Bio


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.


FATE Latest News Stream


Event/Time News Detail
Loading, please wait...

FATE Latest Social Stream


Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about Fate Therapeutics Inc that investors may wish to consider to help them evaluate FATE as an investment opportunity.

Fate Therapeutics: Slowly Getting To An Attractive Position

Since my three previous articles on Fate Therapeutics (FATE), the stock has been falling consistently. The reason is the glacial movement of the company’s very early stage pipeline coupled with an untenably high valuation. The market cap used to be nearly $9bn; currently, it is just $3bn. However, outside of...

Avisol Capital Partners on Seeking Alpha | February 21, 2022

Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying

In this article we present the list of Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Click to skip ahead and see the Top 5 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), and Perrigo Co Plc (NASDAQ:PRGO) were […]

Yahoo | February 20, 2022

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update. In order to pa

Yahoo | February 16, 2022

Was The Smart Money Right About Fate Therapeutics Inc (FATE)?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

Yahoo | February 6, 2022

Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ...

Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.

Yahoo | February 2, 2022

Read More 'FATE' Stories Here

FATE Price Returns

1-mo 11.32%
3-mo -34.14%
6-mo -56.30%
1-year -70.55%
3-year 29.31%
5-year 672.06%
YTD -55.14%
2021 -35.65%
2020 364.64%
2019 52.53%
2018 109.98%
2017 143.43%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5798 seconds.